Suppr超能文献

源自ASC的设计肽对NLRP3炎性小体的选择性抑制作用

Selective inhibition of NLRP3 inflammasome by designed peptide originating from ASC.

作者信息

Sušjan Petra, Lainšček Duško, Strmšek Žiga, Hodnik Vesna, Anderluh Gregor, Hafner-Bratkovič Iva

机构信息

Department of Synthetic Biology and Immunology, National Institute of Chemistry, Ljubljana, Slovenia.

Graduate School of Biomedicine, University of Ljubljana, Ljubljana, Slovenia.

出版信息

FASEB J. 2020 Aug;34(8):11068-11086. doi: 10.1096/fj.201902938RR. Epub 2020 Jul 10.

Abstract

NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome is a multiprotein complex which forms within cells in response to various microbial and self-derived triggers. Mutations in the gene encoding NLRP3 cause rare cryopyrin-associated periodic syndromes (CAPS) and growing evidence links NLRP3 inflammasome to common diseases such as Alzheimer´s disease. In order to modulate different stages of NLRP3 inflammasome assembly nine peptides whose sequences correspond to segments of inflammasome components NLRP3 and apoptosis-associated speck-like protein containing a CARD (ASC) were selected. Five peptides inhibited IL-1β release, caspase-1 activation and ASC oligomerization in response to soluble and particulate NLRP3 triggers. Modulatory peptides also attenuated IL-1β maturation induced by constitutive CAPS-associated NLRP3 mutants. Peptide corresponding to H2-H3 segment of ASC pyrin domain selectively inhibited NLRP3 inflammasome by binding to NLRP3 pyrin domain in the micromolar range. The peptide had no effect on AIM2 and NLRC4 inflammasomes as well as NF-κB pathway. The peptide effectively dampened neutrophil infiltration in the silica-induced peritonitis and when equipped with Antennapedia or Angiopep-2 motifs crossed the blood-brain barrier in a mouse model. Our study demonstrates that peptides represent an important tool for targeting multiprotein inflammatory complexes and can serve as the basis for the development of novel anti-inflammatory strategies for neurodegeneration.

摘要

含NACHT、LRR和PYD结构域蛋白3(NLRP3)炎性小体是一种多蛋白复合物,在细胞内形成以响应各种微生物和自身来源的触发因素。编码NLRP3的基因突变会导致罕见的冷吡啉相关周期性综合征(CAPS),越来越多的证据表明NLRP3炎性小体与阿尔茨海默病等常见疾病有关。为了调节NLRP3炎性小体组装的不同阶段,选择了9种肽,其序列对应于炎性小体成分NLRP3和含CARD的凋亡相关斑点样蛋白(ASC)的片段。5种肽可抑制IL-1β释放、半胱天冬酶-1激活以及对可溶性和颗粒性NLRP3触发因素的ASC寡聚化。调节性肽还减弱了由组成型CAPS相关NLRP3突变体诱导的IL-1β成熟。对应于ASC吡啉结构域H2-H3片段的肽通过在微摩尔范围内与NLRP3吡啉结构域结合来选择性抑制NLRP3炎性小体。该肽对AIM2和NLRC4炎性小体以及NF-κB途径没有影响。该肽有效减轻了二氧化硅诱导的腹膜炎中的中性粒细胞浸润,并且在配备触角足蛋白或血管活性肠肽-2基序时,在小鼠模型中可穿过血脑屏障。我们的研究表明,肽是靶向多蛋白炎症复合物的重要工具,可作为开发神经退行性疾病新型抗炎策略的基础。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验